Quoin Pharmaceuticals, Ltd.
QNRX
$6.69
$0.09141.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.68% | -16.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.86% | 18.29% | |||
| Operating Income | 4.86% | -18.29% | |||
| Income Before Tax | 1.64% | -19.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.64% | -19.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.64% | -19.04% | |||
| EBIT | 4.86% | -18.29% | |||
| EBITDA | 4.91% | -18.51% | |||
| EPS Basic | 24.07% | -19.03% | |||
| Normalized Basic EPS | 24.07% | -19.03% | |||
| EPS Diluted | 24.56% | -20.24% | |||
| Normalized Diluted EPS | 24.07% | -19.03% | |||
| Average Basic Shares Outstanding | 29.52% | 0.00% | |||
| Average Diluted Shares Outstanding | 29.27% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||